Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

Estimated numbers of new cancer cases and deaths in 2025 by cancer site and US state Current cancer incidence, mortality, and ...

Women are now being diagnosed with cancer more often than men in certain age groups, according to a new report from the ...

Cancer diagnoses are expected to exceed two million in 2025, with approximately 618,120 deaths predicted, according to the ...

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...

"I am officially done with radiation, which means I am officially done with what is considered active cancer treatment," ...